

[161] KAHR MEDICAL DUAL SIGNALING PROTEINS (DSP) PLATFORM - THE NEXT GENERATION OF CANCER IMMUNOTHERAPY

Yaron Pereg¹, ¹ Kahr Medical

ABSTRACT TEMPLATE for Company Presentations

Questions for Biotech/Pharma

- **Investment Rational**

KAHR Medical (KAHR) is a platform technology company strategically positioned in the immune-oncology therapeutic area to deliver the next generation of ultra-active, bi-functional, immunotherapeutic drugs rationally designed for the treatment of cancer. The company benefits from a highly experienced management team supported by an advisory board of internationally renowned leaders in the immune-oncology space.
- **Business Strategy**

KAHR plans to aggressively advance its internal preclinical pipeline towards proof-of-concept in humans. KAHR plans to independently advance some of its pipeline products and seek strategic partnerships for co-development or milestone-driven investment associated with other early stage projects. In parallel, development risks will be mitigated by signing co-development or JV deals for use of its DSPs ex-vivo in T-cell therapies.
- **Core Technology**

KAHR's proprietary technology platform allows generation of targeted, immunotherapeutic, dual signaling proteins (DSPs). These chimeric, recombinant proteins have two functional ends that can simultaneously block or activate two reinforcing biological signals resulting in a synergistic outcome. The platform benefits from a rapid screening process, with a lead time from combination selection to small scale production of only 6-8 weeks.

Product Profile/Pipeline

KAHR's early development pipeline includes three DSPs, with the potential to become best-in-class, targeting CD47 (DSP107) or PDL-1 (DSP105 / DSP106) fused with ligands for T-cell costimulatory receptors. DSP107 (SIRP α -41BBL) is in CMC and preclinical development with plans to complete IND-enabling studies by the end of 2019. KAHR seeks licensing, co-development or partnership deals to advance DSP105 / DSP106 development.

- **What's Next?**

KAHR intends to broaden its pipeline with early stage projects during 2018. Next generation DSPs will be modularly designed for selective tumor site or tumor microenvironment targeting. The platform technology is adaptable to most checkpoint targets and will leverage advances in the immune-oncology space. KAHR plans to partner, co-develop these new projects based on proof-of-concept from the current pipeline.